Biopress Journal of Advanced Pharmacology Vol. 1 Issue. 2 (2025)

Pharmacomicrobiomics: Understanding Drug–Microbiota Interactions for Precision Medicine

Sriya Choudhury[1], Pramit Bandyopadhyay[2], Manojit Sinha[3]

[1]*Department of Biochemistry, Institute of Biomedical Sciences, West Bengal University of Health Sciences, West Bengal, India.*

[2]*Department of Biochemistry, Burdwan Institute of Management and Computer Science, Dewandighi, West Bengal, India.*

[3]*Department of Biochemistry, Ballygunge Science College, University of Calcutta, Kolkata, West Bengal, India.*

Corresponding Author: Sriya Choudhury
Email: sriyachoudhury97@gmail.com

Doi: **10.5281/zenodo.17101845**
Received: 25 July 2025
Accepted: 06 August 2025

Abstract

The complex ecosystem of human-associated microorganisms is now recognized as a critical factor influencing how individuals respond to therapeutic drugs. The gut microbiota, in particular, possesses enzymatic functions that can transform various compounds, often altering their intended pharmacological effects. This review explores the mechanisms through which the microbiota mediates drug transformation, including reduction, hydrolysis, and deconjugation, and how these interactions shape inter-individual variability in treatment response. Notably, several commonly prescribed drugs can in turn disrupt microbial equilibrium, leading to imbalances that affect both gastrointestinal and systemic health. Recent studies have suggested that targeted microbial interventions, such as probiotic and synbiotic supplementation, can support the restoration of microbial harmony and potentially improve drug tolerability and effectiveness. Applications of this approach are increasingly being investigated across a wide array of fields, including cancer therapy, mental health, infectious diseases, and autoimmune conditions. A deeper understanding of these interactions holds promise for shaping personalized treatment strategies that account for the patient's unique microbial profile.

Keywords: *microbiota, drug transformation, pharmacomicrobiomics, probiotics, host-microbe interactions*

Introduction

Pharmacomicrobiomics is an emerging interdisciplinary field that investigates the complex interplay between pharmaceutical agents and the human microbiota, with particular focus on gut microbial communities. First introduced by Prof. Marci Candela and formally coined by Rizkallah and colleagues in 2010, this domain emphasizes how microbial populations influence drug metabolism, efficiency and toxicity (Rizkallah *et al*., 2010; Candela *et al*., 2012). The human gut harbors billions of beneficial microorganisms, often referred to as probiotics, which play a crucial role in maintaining immune balance, regulating host metabolism, and supporting overall health (Cani, 2018; Thursby & Juge, 2017).

Recent research has demonstrated that these microbes can impact therapeutic responses both directly and indirectly—either by modifying drug metabolism, influencing drug distribution and targeting, or interacting with host enzymatic pathways (Spanogiannopoulos *et al*., 2016; Wilson & Nicholson, 2017). This two-way relationship, often referred to as drug–microbiota interaction, underscores how microbial communities can affect the pharmacokinetics and pharmacodynamics of medications, while medications themselves can reshape microbial composition and functionality (Zimmermann *et al*., 2019). By integrating insights from pharmacology and microbiology, pharmacomicrobiomics holds significant promise in minimizing interindividual variability in drug responses and advancing the development of tailored treatment strategies for improved clinical outcomes (Zhang & Davies, 2021).

Drug–Microbiota Interactions

In recent years, it has become increasingly evident that the diverse and dense microbial communities residing in the human gastrointestinal tract, collectively referred to as the gut microbiota**,** play a far more active role in human physiology than previously believed. One of their most significant functions pertains to drug metabolism. Rather than serving merely as passive residents, these microbes are now recognized as active biological entities that engage in a complex, bidirectional interaction with pharmaceutical agents. This expanding area of research, termed pharmacomicrobiomics, explores how microbial populations modulate drug efficacy, toxicity, and metabolism, while simultaneously being influenced by these same drugs (Rizkallah *et al*., 2010; Wilson & Nicholson, 2017).

This dynamic interaction has profound implications for therapeutic outcomes. It helps to explain why two individuals receiving the same medication may experience drastically different effects—ranging from full therapeutic success to negligible response or even adverse reactions. Such variability is increasingly being attributed to differences in individual microbiota composition and metabolic potential (Spanogiannopoulos *et al*., 2016). Consequently, integrating microbiome profiling into treatment protocols could revolutionize the concept of personalized medicine, enabling clinicians to tailor drug regimens based not only on genetic factors but also on the unique microbial ecosystem of each patient (Zimmermann *et al*., 2019).

How Gut Microbes Affect Drug Activity

While the gut microbiota can influence drug behavior, the relationship is equally reciprocal—many commonly used medications have the potential to reshape the microbial ecosystem in significant ways. Antibiotics are the most well-known disruptors, often leading to a loss of microbial diversity and the dominance of opportunistic pathogens such as *Clostridioides difficile* (Thursby & Juge, 2017). However, non-antibiotic drugs, including proton pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs), and metformin, have also been shown to alter microbial composition. For instance, PPIs can increase gastric pH, enabling the survival of upper GI microbes and allowing their migration into the intestines, which can lead to small intestinal bacterial overgrowth (SIBO) and dysbiosis (Jackson *et al*., 2016). Metformin, widely used in type 2 diabetes, has been found to increase the abundance of beneficial microbes like *Akkermansia muciniphila*, which may contribute to its glucose-lowering effects (Wu *et al*., 2017). Even statins and antidepressants have demonstrated mild antimicrobial activity, unintentionally affecting gut microbial balance. These shifts can influence nutrient metabolism, immune responses, and, crucially, how other drugs are processed. Understanding these alterations is essential to developing co-therapies that preserve or restore microbial health during pharmacological treatments.

Mechanisms of Drug-Mcrobiota Interactions

The human gut microbiota plays a crucial role in mediating the transformation of drugs through enzymatic activities, including reduction, hydrolysis, and deconjugation. These microbial processes can influence drug efficacy and safety, potentially resulting in therapeutic failure or toxicity. For example, bacterial β-glucuronidases are known to cleave glucuronide drug conjugates, leading to reactivation and potential toxicity—such as seen in the reactivation of irinotecan, an anticancer drug, in the gut after hepatic metabolism (Zimmermann et al., 2019). Other microbial enzymes can modify the chemical structure of drugs, either activating them (as in the case of prodrugs like sulfasalazine) or rendering them inactive (as with digoxin deactivation by Eggerthella lenta) (Haiser et al., 2013; Wilson & Nicholson, 2017). Furthermore, microbial metabolism can produce novel compounds, including harmful intermediates that may interact unfavorably with concurrent medications.The impact of these interactions extends beyond pharmacokinetics to influence pharmacodynamics and overall treatment efficacy. Drugs processed by the liver for excretion may be deconjugated by microbial enzymes in the gut, facilitating enterohepatic recirculation and prolonging systemic exposure, which may enhance therapeutic effects or intensify side effects. Moreover, microbial communities may compete with host pathways for drug metabolism, creating variability in drug bioavailability across individuals. This mechanistic understanding highlights the need for integrating microbiome profiling in clinical decision-making to personalize treatment strategies and avoid undesirable drug outcomes.

Specific Microbial Mechanisms Affecting Drugs

- **Microbial Activation of Prodrugs**
  Certain medications are formulated as inactive compounds and require microbial enzymes to become effective. A classic example is *sulfasalazine*, used for treating inflammatory bowel disease. It becomes pharmacologically active only after gut bacteria cleave it, releasing 5-aminosalicylic acid (Wilson & Nicholson, 2017).
- **Drug Inactivation by Microbes**
  Some microbes can diminish drug efficacy by deactivating them. For instance, the commonly prescribed heart medication *digoxin* can be rendered inactive by *Eggerthella lenta*, a species found in the human gut (Haiser *et al*., 2013).
- **Generation of Toxic Metabolites**
  Microbial metabolism can occasionally produce harmful by-products from otherwise safe drugs. One example is *sorivudine*, an antiviral medication that, when metabolized by gut bacteria, can yield a compound that dangerously interacts with chemotherapy drugs (Spanogiannopoulos *et al*., 2016).
- **Prolonged Drug Exposure via Recirculation**
  Drugs modified by the liver for elimination can be reactivated in the gut by bacterial enzymes, leading to **enterohepatic recirculation**. This prolongs the presence of the drug in the system, sometimes increasing the risk of side effects. The anti-cancer drug *irinotecan* is one such example (Zimmermann *et al*., 2019).



Fig.1 : Impact of Gut Microbiota on Drugs Metabolism and Pharmacokinetics

Tools and techniques in pharmacomicrobiomics

Pharmacomicrobiomics uses a veriety of advance tools and techniques to study the proper interactions of drug and microbiota. Key techniques include 16S rRNA sequencing , shotgun sequencing , bioinfromatics and systems biology. Now we discuss some techniques—

1. **16S rRNA sequencing** – It is the most common housekeeping genetic marker for classifying and identifying the bacterial species.
2. **Shotgun sequencing** – Shotgun metagenome sequencing (SMS), a techniques that provides a boarder characterization of microbial sample by sequencing a large number of genes in each organism.
3. **Metabolomics** – it is a techniques which detect the exact microbial metabolism that influence the drugs efficiency and its toxicity.
4. **Bioinfromatics and system biology** – it is mainly use the predict and model of drug-microbiota interaction.
5. **Transcriptomics** – it is mainly the study of the gene expression , at here we use the understanding how drugs affects the individuals.

Clinical Implications and Precision Medicine

The discovery that gut microbes can influence how our bodies process medications has opened new possibilities in clinical medicine. While pharmacogenomics has long aimed to explain why people respond differently to the same drug, it often falls short. Now, pharmacomicrobiomics provides an additional explanation—highlighting how the diversity and activity of gut microbes can affect how drugs are broken down, absorbed, or even rendered toxic. For example, specific bacterial strains have been shown to inactivate drugs like digoxin or convert cancer drugs into harmful compounds, offering an explanation for side effects seen in only some patients (Haiser et al., 2013; Spanogiannopoulos et al., 2016). Likewise, the response to cancer immunotherapy has been linked to certain microbiota compositions, and studies suggest that transplanting healthy gut bacteria may help improve treatment outcomes in some cases (Matson et al., 2018; Zimmermann et al., 2019).

This understanding has important clinical consequences. By analyzing a person's microbiome, doctors could soon predict how well they'll respond to a particular medication—or if they're likely to face complications. This could help reduce trial-and-error prescribing, especially in areas like cancer, gut disorders, or mental health conditions where microbiota–drug interactions play a large role (Zhang & Davies, 2021). In addition, supplementing treatment with beneficial microbes—such as probiotics or synbiotics—is being tested to improve drug effectiveness or reduce side effects. For instance, when combined with antibiotics or chemotherapy, some probiotics may help restore balance in the gut, supporting recovery and reducing damage to the gut environment (Cani, 2018; Thursby & Juge, 2017). These developments suggest that personalized medicine will not only be shaped by our genes but also by our gut.

Therapeutic Strategies Based on Microbiome Modulation

Growing recognition of the gut microbiota's role in health has inspired new strategies to protect or restore its balance during medical treatments. One approach involves probiotics—live bacteria that, when consumed in the right amounts, may help stabilize the gut environment. Strains such as *Lactobacillus* and *Bifidobacterium* have been shown to ease digestive side effects caused by antibiotics or chemotherapy and may even improve drug effectiveness (Ouwehand et al., 2002). In parallel, prebiotics, which are food ingredients that nourish beneficial microbes, promote microbial diversity and resilience. Used together, synbiotics—a combination of prebiotics and probiotics—can be more effective at supporting gut health during treatment recovery (Swanson et al., 2020). In recent years, scientists have also begun designing engineered probiotics—bacteria modified to deliver therapeutic compounds, detoxify harmful substances, or regulate inflammation. These developments mark a shift from simply delivering drugs to actively managing how the body and microbiome respond to them, offering a more tailored and protective approach to therapy (Charbonneau et al., 2020).

- **Probiotics**: Live microbes that can replenish beneficial bacteria during antibiotic or chemotherapy regimens. Examples include *Lactobacillus* and *Bifidobacterium* (Ouwehand et al., 2002).
- **Prebiotics**: Non-digestible fibers that fuel the growth of health-promoting bacteria.
- **Synbiotics**: Combinations of prebiotics and probiotics that enhance microbial diversity and resilience.
- **Engineered Probiotics**: Genetically modified strains designed to detoxify harmful compounds, produce therapeutic molecules, or modulate immune responses (Charbonneau et al., 2020).



Fig.2 : Dual role of Drug microbiota in Drug Responses

Conclusion

The evolving field of pharmacomicrobiomics has introduced a new perspective in biomedical research, demonstrating that the gut microbiota is not merely a passive inhabitant of the human body but a dynamic participant in determining drug behaviour. These microbial communities have been shown to activate, deactivate, and even alter the toxicity of various therapeutic compounds. This understanding provides a valuable explanation for the wide variation in how individuals respond to the same medication and suggests that microbiota-based differences may be just as important as genetic factors in influencing drug outcomes.

Equally important is the realization that medications can significantly alter the microbial balance, leading to unintended consequences such as reduced drug efficacy or increased side effects. These bidirectional interactions highlight the need to rethink how treatments are designed and administered. Looking forward, incorporating gut microbiome profiles into clinical decision-making could significantly enhance the effectiveness of therapy. Interventions such as probiotics, synbiotics, and even microbiota-based engineering show promise in maintaining microbial balance and enhancing patient recovery. Supported by advanced analytical platforms like metagenomics, metabolomics, and transcriptomics, pharmacomicrobiomics is paving the way for a more individualized and holistic approach to treatment—where therapies are informed not only by human genes but also by the microbial companions within us.

References

1. Candela, M., Turroni, S., Biagi, E., Carbonero, F., Rampelli, S., Fiorentini, C., & Brigidi, P. (2012). Inflammation and gut microbiota: A new key player in chronic diseases. *Nature Reviews Gastroenterology & Hepatology, 9*(10), 599–608.
2. Cani, P. D. (2018). Human gut microbiome: Hopes, threats and promises. *Gut, 67*(9), 1716–1725.
3. Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020). Developing a new class of engineered live bacterial therapeutics to treat human diseases. *Nature Communications, 11*, 1738.
4. Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2013). Predicting and manipulating cardiac drug inactivation by the human gut bacterium *Eggerthella lenta*. *Science, 341*(6143), 295–298.
5. Jackson, M. A., Goodrich, J. K., Maxan, M. E., Freedberg, D. E., Abrams, J. A., Poole, A. C., & Spector, T. D. (2016). Proton pump inhibitors alter the composition of the gut microbiota. *Gut, 65*(5), 749–756.
6. Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M. L., & Gajewski, T. F. (2018). The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. *Science, 359*(6371), 104–108.
7. Ouwehand, A. C., Salminen, S., & Isolauri, E. (2002). Probiotics: An overview of beneficial effects. *Antonie van Leeuwenhoek, 82*(1), 279–289.
8. Rizkallah, M. R., Saad, R., & Aziz, R. K. (2010). The human microbiome project: Personalized medicine of the future. *The Human Genomics, 4*(3), 228–234.
9. Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016). The microbial pharmacists within us: A metagenomic view of xenobiotic metabolism. *Nature Reviews Microbiology, 14*(5), 273–287.

10. Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., & Scott, K. (2020). The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. *Nature Reviews Gastroenterology & Hepatology, 17*(11), 687–701.
11. Thursby, E., & Juge, N. (2017). Introduction to the human gut microbiota. *Biochemical Journal, 474*(11), 1823–1836.
12. Wilson, I. D., & Nicholson, J. K. (2017). Gut microbiome interactions with drug metabolism, efficacy, and toxicity. *Translational Research, 179*, 204–222.
13. Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., & Bäckhed, F. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. *Nature Medicine, 23*(7), 850–858.
14. Zhang, L., & Davies, S. S. (2021). Microbial metabolism and drug response: Pharmacokinetics and beyond. *Pharmacological Reviews, 73*(3), 1145–1165.
15. Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019). Mapping human microbiome drug metabolism by gut bacteria and their genes. *Nature, 570*(7762), 462–467.